BiotechTube

Etirinotecan pegol

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anaplastic Astrocytomas

Conditions

Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas, Glioblastomas (GBM)

Trial Timeline

Jul 1, 2012 → Feb 1, 2015

NCT ID
NCT01663012

About Etirinotecan pegol

Etirinotecan pegol is a phase 2 stage product being developed by Nektar Therapeutics for Anaplastic Astrocytomas. The current trial status is completed. This product is registered under clinical trial identifier NCT01663012. Target conditions include Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas, Glioblastomas (GBM).

What happened to similar drugs?

0 of 1 similar drugs in Anaplastic Astrocytomas were approved

Approved (0) Terminated (0) Active (1)
🔄Alectinib + CrizotinibRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01663012Phase 2Completed

Competing Products

20 competing products in Anaplastic Astrocytomas

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
24
efatutazone + paclitaxelDaiichi SankyoPhase 2
35
Lenvatinib 24 mgEisaiPhase 2
27
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
39
durvalumab + tremelimumabAstraZenecaPhase 1
29
PembrolizumabMerckPhase 2
35
LDK378 + AUY922NovartisPhase 1
29
ceritinibNovartisPre-clinical
30
LDK378NovartisPhase 1
29
CeritinibNovartisPhase 2
27
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastimNovartisPhase 1
29
dabrafenib/trametinibNovartisPhase 2
42
Trametinib + PaclitaxelNovartisPhase 1
33
Alectinib + CrizotinibRochePhase 3
44
Sunitinib MalatePfizerPhase 2
35
Crizotinib (PF-02341066)PfizerPhase 2
35
LorlatinibPfizerPhase 2
31
CrizotinibPfizerPhase 1/2
32
Cemiplimab + XL092Regeneron PharmaceuticalsPhase 1
36
BevacizumabNovocurePhase 2
36